Literature DB >> 9427702

Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not.

B Kehrel1, S Wierwille, K J Clemetson, O Anders, M Steiner, C G Knight, R W Farndale, M Okuma, M J Barnes.   

Abstract

Simple collagen-related peptides (CRPs) containing a repeat Gly-Pro-Hyp sequence are highly potent platelet agonists. Like collagen, they must exhibit tertiary (triple-helical) and quaternary (polymeric) structure to activate platelets. Platelet signaling events induced by the peptides are the same as most of those induced by collagen. The peptides do not recognize the alpha 2 beta 1 integrin. To identify the signaling receptor involved, we have evaluated the response to the CRP, Gly-Lys-Hyp(Gly-Pro-Hyp)10-Gly-Lys-Hyp-Gly of platelets with defined functional deficiencies. These studies exclude a primary recognition role for CD36, von Willebrand factor (vWF), or glycoprotein (GP) IIb/IIIa. Thus, both CD36 and vWF-deficient platelets exhibited normal aggregation, normal fibrinogen binding, and normal expression of CD62 and CD63, measured by flow cytometry, in response to the peptide, and there was normal expression of CD62 and CD63 on thrombasthenic platelets. In contrast, GPVI-deficient platelets were totally unresponsive to the peptide, indicating that this receptor recognizes the Gly-Pro-Hyp sequence in collagen. GPVI-deficient platelets showed some fibrinogen binding in response to collagen but failed to aggregate and to express CD62 and CD63. Collagen, but not CRP-XL, contains binding sites for alpha 2 beta 1. Therefore, it is possible that collagen still induces some signaling via alpha 2 beta 1, leading to activation of GPIIb/IIIa. Our findings are consistent with a two-site, two-step model of collagen interaction with platelets involving recognition of specific sequences in collagen by an adhesive receptor such as alpha 2 beta 1 to arrest platelets under flow and subsequent recognition of another specific collagen sequence by an activatory receptor, namely GPVI.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427702

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Inhibition of human platelet adenylate cyclase activity by adrenaline, thrombin and collagen: analysis and reinterpretation of experimental data.

Authors:  A Juska; R W Farndale
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

Review 2.  [Pathophysiology and biochemistry of platelets].

Authors:  K Jurk; B E Kehrel
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

3.  Loss of GPVI and GPIbα contributes to trauma-induced platelet dysfunction in severely injured patients.

Authors:  Paul Vulliamy; Samantha J Montague; Scarlett Gillespie; Melissa V Chan; Lucy A Coupland; Robert K Andrews; Timothy D Warner; Elizabeth E Gardiner; Karim Brohi; Paul C Armstrong
Journal:  Blood Adv       Date:  2020-06-23

Review 4.  Recent Insights Into the Regulation of Coagulation and Thrombosis.

Authors:  Xian Li; Martha M S Sim; Jeremy P Wood
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-22       Impact factor: 8.311

5.  hnRNP L regulates differences in expression of mouse integrin alpha2beta1.

Authors:  Yann Cheli; Thomas J Kunicki
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

6.  Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood.

Authors:  Nicholas Pugh; Anna M C Simpson; Peter A Smethurst; Philip G de Groot; Nicolas Raynal; Richard W Farndale
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

7.  State of the art in platelet function testing.

Authors:  Beate E Kehrel; Martin F Brodde
Journal:  Transfus Med Hemother       Date:  2013-03-18       Impact factor: 3.747

8.  Hematopoietic lineage cell specific protein 1 (HS1) is a functionally important signaling molecule in platelet activation.

Authors:  Bryan N Kahner; Robert T Dorsam; Sripal R Mada; Soochong Kim; Timothy J Stalker; Lawrence F Brass; James L Daniel; Daisuke Kitamura; Satya P Kunapuli
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

9.  A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex.

Authors:  Hiroshi Takayama; Yoshitaka Hosaka; Kazuyuki Nakayama; Kamon Shirakawa; Katsuki Naitoh; Tomokazu Matsusue; Mikihiko Shinozaki; Motoyasu Honda; Yukiko Yatagai; Tetsushi Kawahara; Jiro Hirose; Tooru Yokoyama; Michiru Kurihara; Shoji Furusako
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 10.  In vitro megakaryocyte production and platelet biogenesis: state of the art.

Authors:  Jo-Anna Reems; Nicolas Pineault; Sijie Sun
Journal:  Transfus Med Rev       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.